by Sara M. Nolte | Jan 19, 2015
. If you’ve been on the Internet at all in 2015, you’ve probably stumbled across headlines like “Two-thirds of cancers are due to ‘back luck,’ study finds” (CBSNews), “Most cancers are caused by bad luck not genes or lifestyle say scientists” (The Telegraph), “Cause...
by Mark Curtis | Jan 13, 2015
. Welcome to your Update from the Clinic for the month of December. bluebird bio’s first four patients are transfusion-free after treatment with its gene therapy Lentiglobin. Fate Therapeutics’ hematopoietic stem cell-modulating technology ProHema seems to be on track...
by Mark Curtis | Dec 23, 2014
. Welcome to your Update from the Clinic for the month of November. NeoStem announced initial positive data from its Phase 2 study in acute myocardial infarction. Neuralstem’s human neural stem cells are shown to have long-term viability following transplant, while...
by James Smith | Dec 18, 2014
. With contributions from David Brindley Manufacturing may not be the first thing that springs to mind when regenerative medicine is mentioned. Most will think of the enormous potential for cell therapies or transplantation or editing of faulty genes. However, having...
by Sara M. Nolte | Dec 8, 2014
> In my previous toolbox articles (sphere formation and xenotransplantation), I’ve talked about assays that are pretty useful in determining the existence of cancer stem cell (CSC) populations based on function. What these assays cannot do is provide us with a way...
by Mark Curtis | Dec 4, 2014
. The Edmonton Protocol for the transplantation of insulin producing cells into individuals with type 1 diabetes (T1DM) has a cost per quality-adjusted life year (QALY) of ~$165,000. This is more than three times the willingness-to-pay (WTP) in Canada, and comfortably...
Comments